Skip to main content

Table 2 Summary of AEs occurring in ≥ 15% of patients

From: Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)

AE, n (%)

N = 74

Any grade

Grade ≥ 3

Any AE

74 (100)

45 (60.8)

Hematologic

  Leukopenia

32 (43.2)

19 (25.7)

  Thrombocytopenia

31 (41.9)

14 (18.9)

  Anemia

22 (29.7)

11 (14.9)

Non-hematologic

  Pyrexia

68 (91.9)

11 (14.9)

  Increased AST

28 (37.8)

15 (20.3)

  Hypotension

14 (18.9)

4 (5.4)

  Increased ALT

13 (17.6)

0

  Cough

13 (17.6)

1 (1.4)

Cytokine release syndrome

68 (91.9)

7 (9.5)a

Neurotoxicity

1

0

  1. AE adverse event, AST aspartate transaminase, ALT, alanine aminotransferase, CRS cytokine release syndrome
  2. a1 patient died 13 days post-treatment due to grade 5 CRS